جستجوی استاد راهنمای دانشگاهی

Xian Wuمشاهده پروفایل

استادیار

• Developmental Toxicology
• Stem Cell Models
• Neurotoxicology
• +۵ مورد دیگر

Xian Wu, Ph.D., serves as a Research Assistant Professor in the Department of Pharmacology & Toxicology at East Carolina University's Brody School of Medicine. Her research leverages human stem cell models to investigate developmental vulnerabilities to environmental contaminants in cardiovascular and neural systems, with emphasis on epigenetic mechanisms and disease modeling. Dr. Wu's academic credentials include: Ph.D. in Toxicology from the University of Georgia M.S. in Biomedicine from East China Normal University B.S. in Biotechnology from Anhui University Her postdoctoral training comprised a Fellowship at the National Institute of Environmental Health Sciences and an ORISE Fellowship at the U.S. Food and Drug Administration. Research focuses on creating human stem cell-derived organoid systems to model developmental toxicology, particularly examining cardiac and neural development under chemical exposure. The laboratory employs fluorescence reporter systems and RNA-seq to identify critical vulnerability windows during early development, with recent work targeting Parkinson's disease mechanisms through dopaminergic neuron models and cardiac fibrosis via advanced organoids. Methodological innovations include high-content imaging for neurogenesis quantification and epigenetic pathway analysis. Publication trends (2016-2025) demonstrate consistent advancement in stem cell-based toxicology testing, with increasing emphasis on micro/nanoplastics risk assessment, arsenic neurotoxicity mechanisms, and doxorubicin cardiotoxicity modeling. The work bridges environmental health, epigenetics, and regenerative medicine through interdisciplinary approaches. Scientific recognition includes: 2025 SPARC Award (ECU) 2024 Top Abstract Award (Developmental Origins of Health and Disease Society) 2024 NIEHS P30 Center Travel Award 2023 ECU Research and Creative Activity Award Dr. Wu actively mentors graduate researchers including Ph.D. candidate Cate Duncan and M.S. students Kamilah Muhammad and Bailey Skeen, alongside undergraduate Bryce Tilghman. Former trainees McKyrah Brown and Monica Cross completed honors theses in the laboratory. Current grants include ECU's SPARC Award funding stem cell model development for environmental contaminant testing. The BSOM 6S-11 laboratory maintains specialized capabilities in cardiac and cerebral organoid generation, fluorescence-based toxicity screening, and RNA-seq epigenetic analysis. Collaborative networks include the National Institute of Environmental Health Sciences and ECU's Center for Human Health and the Environment, supporting translational research on developmental vulnerability periods.

James Lacefieldمشاهده پروفایل

استاد

• Biomedical Ultrasound Imaging
• Vascular Imaging
• Cancer Research Applications
• +۵ مورد دیگر

James Lacefield is a Professor in both the Department of Electrical and Computer Engineering and the Department of Medical Biophysics at Western University. He serves as Director of the School of Biomedical Engineering and maintains his research laboratory in the Amit Chakma Engineering Building. His academic appointments span multiple disciplines, reflecting the interdisciplinary nature of his work in biomedical ultrasound imaging. Dr. Lacefield earned his Ph.D. and B.S.E. in Biomedical Engineering from Duke University. His educational background established the foundation for his current research program that bridges engineering principles with medical applications. His research focuses on the physical acoustics and signal processing aspects of ultrasound imaging, with particular emphasis on quantitative vascular imaging applications. Dr. Lacefield's laboratory develops novel methods for color Doppler, power Doppler, and contrast-enhanced ultrasound imaging, with primary applications in cancer research. Current projects include optimization of high-resolution ultrasound systems for tumor vascular characterization and development of methods to quantify spatial blood flow distribution in tumors. Analysis of his recent publications reveals a strong focus on quantitative ultrasound techniques for cancer applications, with particular attention to tumor perfusion assessment using contrast-enhanced ultrasound. His work demonstrates increasing sophistication in speckle analysis methods to improve the reliability of perfusion measurements in preclinical tumor models. Associate Editor, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control Member, Council of Chairs of Bioengineering and Biomedical Engineering Member, College of Reviewers, Canadian Institutes of Health Research Dr. Lacefield maintains active collaborations with multiple research groups including the Imaging Research Laboratories at Robarts Research Institute. His professional activities include editorial work for major ultrasound journals and participation in national review panels for biomedical research funding.

• Breast Cancer
• Chemotherapy
• Pharmacology
• +۷ مورد دیگر

Della F. Makower, M.D. is an Oncology specialist at Montefiore Medical Center with a robust research portfolio focusing on breast cancer treatment, chemotherapy effects, and health disparities. With 49 publications and an h-index of 21, she has made significant contributions to understanding cancer treatment outcomes, particularly regarding social determinants of health and racial disparities in cancer care. Her research interests span multiple critical areas in oncology including: Breast Cancer (100% research focus) Chemotherapy (76% research focus) Recurrent Disease (61% research focus) Malignant Neoplasm (44% research focus) Endocrine Therapy (30% research focus) Hormone Receptor research (25% research focus) Dr. Makower's recent publications demonstrate a strong emphasis on health equity, with multiple studies examining racial disparities in cardiotoxicity, the impact of social determinants on cancer treatment outcomes, and specialized research on breast cancer in diverse patient populations. Her work frequently appears in high-impact journals including the Journal of the American Heart Association, Breast Cancer Research and Treatment, Cancer, and the Journal of Clinical Oncology. Notable research initiatives include: ECOG-ACRIN EA1131 trial comparing adjuvant platinum versus capecitabine for triple-negative breast cancer ECOG-ACRIN EAZ171 trial investigating germline predictors of taxane-induced neuropathy in Black women with breast cancer Studies examining the relationship between social determinants of health and anthracycline cardiotoxicity Research on the impact of the COVID-19 pandemic on breast cancer screening and diagnosis Her collaborative approach is evident in the multi-institutional nature of her research, with frequent collaborations across major cancer research networks. Dr. Makower's work has garnered significant attention, with multiple studies picked up by news outlets and discussed on social media platforms including X (Twitter) and Facebook.

Deok-Ho Kimمشاهده پروفایل

استاد

• Stem cell engineering
• Tissue engineering
• Organs-on-chips
• +۷ مورد دیگر

Deok-Ho Kim, PhD, is a Professor in the Department of Biomedical Engineering at Johns Hopkins University. His research focuses on integrating nanotechnology, biomaterials, and mechanobiology to advance tissue engineering, regenerative medicine, and disease modeling. Key areas include stem cell engineering, organs-on-chips, and bio-inspired materials for drug screening and cell-based therapies. Education: PhD in Biomedical Engineering from Johns Hopkins University (2010), MS in Mechanical Engineering from Seoul National University (2000), and BS in Mechanical Engineering from POSTECH (1998). Research emphasizes understanding how mechanical and biochemical signals regulate cell behavior in health and disease. Notable work includes microphysiological systems (MPS) for precision medicine, spaceflight effects on cardiac function, and engineered heart tissue models. Recent studies highlighted the impact of microgravity on heart cells and the role of LOXL2 in hypertension. Laboratory: Kim Lab develops cutting-edge tools like nanopatterned electrodes and biomimetic substrates. Collaborations span academia and industry, with media features in Scientific American and coverage of heart-on-a-chip studies in space. Grants and Funding: Active in securing federal and foundation grants for tissue engineering and biomaterials research. Advising: No formal student list provided, but mentors trainees in multidisciplinary approaches.

Tiina Sikanenمشاهده پروفایل

دانشیار

• Microfluidic Total Analysis Systems
• Digital Microfluidics
• Polymer Microfabrication
• +۵ مورد دیگر

Tiina Sikanen is an Associate Professor at the University of Helsinki within the Faculty of Pharmacy, Division of Pharmaceutical Chemistry and Technology . She leads the Chemical Microsystems Lab and serves as a supervisor for doctoral programmes in Drug Research, Chemistry and Molecular Sciences, and Materials Research and Nanosciences. Her research focuses on microfluidic systems, polymer microfabrication, and mass spectrometry applications in drug metabolism studies. Education : MSc in Chemical Technology (Aalto University, 2010), PhD in Pharmaceutical Chemistry (University of Helsinki, 2007) Her research integrates microfluidic total analysis systems with digital microfluidics to create 3D liver and cardiac cell culture models for studying extracellular vesicle activity and cytochrome P450 metabolism. Key projects include PREMIER (risk evaluation of medicines in environment) and CardioEV (cardiotoxicity biomarker discovery). Her recent publications highlight advancements in microdevice-based extracellular vesicle quantitation, Staphylococcus biofilm modeling, and sustainable pharmaceutical life-cycle analysis. Scientific awards include the Academy of Finland Award for Scientific Courage (2019) , Research Fellow (2017) , and Postdoctoral Researcher (2011) . She has supervised numerous Master's and doctoral theses, including Elina Kyllönen's MSc(Pharm) work on microfluidic sustainability challenges and Laura Sirviö's BSc research. Her lab employs 3D printing for cleanroom-free microdevice fabrication and participates in EU-funded initiatives like IMI2-RIA PREMIER.

Bianxiao Cuiمشاهده پروفایل

استاد

• Biophysics
• Cell Biology
• Chemistry
• +۶ مورد دیگر

Professor Bianxiao Cui is the Job and Gertrud Tamaki Professor of Chemistry at Stanford University and a fellow of the Wu Tsai Stanford Neuroscience Institute. Her research integrates biophysics, cell biology, chemistry, and nanotechnology to develop tools for studying the nano-bio interface, membrane curvature, electrophysiology, and signal transduction in health and disease. Ph.D. in Chemistry, University of Chicago (2002) B.S. in Material Science & Engineering, University of Science & Technology of China (1998) Her group bridges biochemistry, material science, and neuroscience to probe cellular processes at nanoscale. Key projects include: Mechanisms of Membrane Curvature: How nanoscale topography regulates integrin adhesions, ER-PM contacts, and ion channel activity. Electrophysiological Tools: Nanoelectrode arrays (NEAs) and electrochromic optical recording (ECORE) for scalable, label-free action potential monitoring. Protein Relocalization: Using shuttle proteins to rewire subcellular localization for disease intervention. Recent articles highlight advancements in 3D cell adhesion , AI-driven electrophysiology , and optogenetic pain models . Her work spans biochemical assays, nanofabrication, and in vivo studies . Scientific Awards: Ono Pharma Breakthrough Science Initiative Award (2022-2025) NIH New Innovator Award (2012-2017) NSF CAREER and INSPIRE Awards Packard and Searle Fellowships Teaching & Advising: She mentors PhD students in Chemistry and Biophysics, including Krishna Raghavan and Pengwei Sun , and supervises postdoctoral fellows like Dr. Wei Zhang . She teaches Biophysical Chemistry and advises on cellular nanomechanics and optogenetics . Labs & Collaborations: The Cui Lab collaborates with the Melosh and Khosla labs, focusing on cell-material interactions and neurotechnology development (e.g., Kirigami electronics for organoid stimulation).

Lupei Duمشاهده پروفایل

دانشیار

• Medicinal Chemistry
• Pharmacology
• Computational Drug Design
• +۴ مورد دیگر

Lupei Du is an Associate Professor at the Department of Medicinal Chemistry, School of Pharmacy, Shandong University, China. He earned his B.S. and Ph.D. in Pharmaceutical Chemistry from China Pharmaceutical University (1999 and 2006) and completed postdoctoral research in Chemistry at Georgia State University (2006–2009). Research focuses on potassium channel blockers for antiarrhythmic agents Specializes in pharmacophore modeling, molecular docking, and fluorescent probe development Contributed to computational drug discovery and structure-activity relationship studies His publications highlight trends in cardiovascular drug design (targeting I Kr , I Ks , and Kv1.5 channels) and fluorescent probe engineering for hydrogen peroxide and carbohydrate detection. Awards include the Nanjing Outstanding Thesis Award (2005) and multiple fellowships. Lupei Du collaborates extensively through co-authorships and is a member of the China Pharmaceutical Association.

• Emergency Medicine
• Medical Toxicology
• Drug Overdose
• +۴ مورد دیگر

Alex F. Manini, MD, MS, is a Professor of Emergency Medicine at the Icahn School of Medicine at Mount Sinai, where he practices clinically at Elmhurst Hospital Center in New York City. He serves as the Director of the Mount Sinai Center for Research on Emerging Substances, Poisoning, Overdose, and New Discoveries (RESPOND Center), and the Associate Program Director of the T32 Clinician Scientist Training Program focused on emergency care research. Dr. Manini earned his Bachelor of Science from MIT, Doctor of Medicine from UCSF School of Medicine, completed his Emergency Medicine Residency at Harvard Affiliated Emergency Medicine Residency (Brigham & Women's Hospital / Massachusetts General Hospital), and Medical Toxicology Fellowship at NYU/Bellevue where he also earned a Master of Science in Clinical Investigation. Dr. Manini's research focuses on emergency medicine and medical toxicology, with particular expertise in drug overdose, opioid-related emergencies, cardiovascular complications of drug overdose, and novel substances of abuse. His work aims to develop clinical tools to individualize prevention strategies for curtailing the national rise in drug overdose fatalities through risk prediction instruments, laboratory biomarkers, and genetic analyses. He has published over 110 peer-reviewed articles in the emergency medicine and medical toxicology literature. Analysis of Dr. Manini's recent publications reveals a strong focus on emerging drug threats, particularly novel synthetic opioids like nitazenes and fentanyl analogs, as well as the increasing prevalence of xylazine and other adulterants in the illicit drug supply. His research spans emergency department management protocols, health disparities in overdose treatment, and the intersection of mental health and substance use disorders. Scientific Awards: Fellow of the American College of Medical Toxicology (FACMT) Young Investigator of the Year, Society of Academic Emergency Medicine (SAEM) NIH Study Section Member, CEBRA (Cutting Edge Basic Research Awards) NIH Early Career Reviewer (ECR), Center for Scientific Review Young Investigator Award WINNER, XXXIII International Congress EAPCCT The Dr. Harold and Golden Lamport Research Award, Mount Sinai School of Medicine Dr. Manini has been continuously funded by the National Institutes of Health (NIH) since 2009, totaling over $10 million as a principal investigator. He has mentored over 40 pre- and post-doctoral students, residents, and junior faculty who have secured millions in federal grant funding. His major grants include an R01 from NIDA studying risk prediction for overdose fatalities, an R56 as Site PI for the NIDA National Early Warning System Network (iN3), and a K23 Career Development Award. As Director of the RESPOND Center (Research on Emerging Substances, Poisoning, Overdose, and New Discoveries), Dr. Manini leads a multidisciplinary team focused on identifying emerging drug threats and developing evidence-based approaches to manage novel substances of abuse. His work bridges emergency medicine, toxicology, cardiology, and public health to address the evolving overdose epidemic.

• Cardio-Oncology
• Medical Education
• Valvular Disease
• +۲ مورد دیگر

Eric Hao Ming Yang is a Clinical Professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA). His clinical and research focus centers on Cardio-Oncology, with expertise in valvular disease, cardiac imaging, and cancer therapy-related cardiovascular toxicity. He is actively engaged in medical education and health disparities research. Education/Training: M.D., University of Illinois at Chicago College of Medicine (2005) Internal Medicine Residency, Harbor-UCLA Medical Center (2008) Cardiovascular Diseases Fellowship, Harbor-UCLA Medical Center (2011) Research Focus: Dr. Yang investigates cardiovascular complications in cancer patients, including chemotherapy-induced cardiotoxicity, immune checkpoint inhibitor myocarditis, and vascular disease. He emphasizes imaging applications (CT, echocardiography) and disparities in cardio-oncology outcomes. His work merges clinical care with translational research to optimize survivorship. Publication Trends: Recent articles (2022-2025) highlight Cardio-Oncology guideline development, imaging innovations, and socioepidemiologic disparities. Dominant themes include SGLT2 inhibitor cardioprotection, immune-related toxicities, and procedural outcomes in high-risk populations like cancer survivors undergoing valve interventions.

• Neurotoxicology
• Toxicology
• In Vitro Toxicology
• +۶ مورد دیگر

Remco Westerink is Associate Professor at Utrecht University's Faculty of Veterinary Medicine and head of the Neurotoxicology Research Group at the Institute for Risk Assessment Sciences (IRAS). His work focuses on cellular and molecular mechanisms of neurotoxicants in food, drugs, and environmental pollutants. Expertise Areas: In vitro toxicology, developmental neurotoxicology, neuropharmacology, microplastics, risk assessment of chemicals Techniques: Multi-electrode arrays, calcium imaging, PC12 cell models, human iPSC-derived neurons Research explores how pollutants like pesticides, flame retardants, and microplastics affect brain development, function, and degeneration through key projects including EU-funded initiatives (TUBE, ENDpoiNTs) and national collaborations. Recent articles highlight his team's work on neurotoxic effects of: Microplastics crossing blood-brain barrier Bisphenols and PFAS disrupting neuronal networks Insecticides altering calcium signaling Organophosphate flame retardants (TCP) linked to aerotoxic syndrome Designer drugs affecting neurotransmission Scientific Contributions: Editorial Board: NeuroToxicology , Toxicology in Vitro Keynote Speaker: 1st International Congress on Global Environmental Contamination (2014) Invited Talks: International Neurotoxicology Association meetings (2012-2017) Westerink leads research into advanced in vitro models to replace animal testing, including development of 48-well microelectrode array platforms and collaborations with Mimetas and RIVM for organ-on-a-chip technology.

C. Michael Gibsonمشاهده پروفایل

استاد پژوهش

• Interventional Cardiology
• Cardiovascular Research
• Clinical Trials
• +۳ مورد دیگر

C. Michael Gibson, MD is a leading interventional cardiologist, cardiovascular researcher, and educator at Harvard Medical School , where he serves as the Chief Executive Officer of the Baim Institute and PERFUSE Research Institute . These institutes have led over 1,000 studies and 5,500 peer-reviewed publications, including 144 in the New England Journal of Medicine . Key Roles: Director of Coronary Care Unit, Cardiac Catheterization Laboratory Director, Chief of Cardiology, Vice Chairman of Medicine Education: BS, MS, and MD from the University of Chicago (Phi Beta Kappa, AOA), followed by training at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center Research Focus: Pioneered the open artery and microvasculature hypothesis in heart attacks, developed widely used coronary blood flow measures (TIMI frame count, TIMI myocardial perfusion grade), and leads virtual clinical trials like the HEARTLINE trial of the Apple Watch. Current work includes Factor XI inhibitors (milvexian) and apolipoprotein AI infusions for cardiovascular disease. Scientific Contributions: Over 148,000 citations, 659 publications, and leadership in guidelines like the Bleeding Academic Research Consortium . Notable trials include ANDexanet Alfa for anticoagulant reversal and the PEERLESS study comparing mechanical thrombectomy to thrombolysis in pulmonary embolism. Leadership: FDA Cardiorenal Panel member (2017–2021), founder of WikiDoc.org and ClinicalTrialsResults.org Media Influence: Chief Medical Correspondent for the American College of Cardiology, 435K+ social media followers Scientific Awards: Consistently ranked among the world’s most highly cited authors (Thomson Reuters, 2014–present), 50 Most Influential Voices in Healthcare (Medika Life, 2021), and Boston’s Top Doctors (multiple years).

• Food sciences
• Functional food chemistry
• Bioorganic chemistry
• +۴ مورد دیگر

Yoichi Nakao is a Professor at the School of Advanced Science and Engineering, Faculty of Science and Engineering, Waseda University, specializing in natural products chemistry, chemical biology, and functional food chemistry. His research focuses on marine natural products, stem cell differentiation, and epigenetics, with significant contributions to understanding how natural compounds affect cellular processes. Dr. Nakao earned his Doctor of Agriculture from the University of Tokyo. His educational background includes undergraduate, master's, and doctoral studies all completed at the University of Tokyo between 1985 and 1994, followed by postdoctoral research at the University of Hawai'i Department of Chemistry from 1994-1996. His research spans multiple interdisciplinary fields with a particular emphasis on identifying bioactive compounds from natural sources. Nakao's work explores how marine organisms and traditional food sources produce compounds that influence stem cell differentiation, particularly neural stem cells into astrocytes, and how these processes relate to neurodegenerative diseases and depression. His laboratory investigates epigenetic modifications induced by environmental chemicals and natural products, with implications for developmental toxicology and disease prevention. A significant portion of his recent work focuses on sustainable applications, including serum-free cell culture systems using algal extracts for cultured meat production and regenerative medicine. Analysis of Nakao's recent publications reveals a strong focus on marine natural products chemistry, with numerous discoveries of novel compounds from sponges, cyanobacteria, and other marine organisms. His research increasingly integrates chemical biology approaches with stem cell technology, particularly using induced pluripotent stem cells to study epigenetic changes. There's also a growing emphasis on sustainable biotechnology applications, especially in developing alternatives to animal serum for cell culture, which has significant implications for cultured meat production and regenerative medicine. Dr. Nakao serves in various professional capacities, including as a committee member for the Natural Products Discussion Group (2011-present), the Japanese Society of Chemical Biology (2010-present), and the Chemical Ecology Research Group (2007-present). He is an active member of numerous professional societies including the American Chemical Society, Japanese Bioinformatics Society, and Japanese Society of Chemistry. His laboratory maintains active collaborations across multiple disciplines, working with researchers in microbiology, parasitology, and biomedical engineering. Current research directions include developing chemical probes for target identification, studying microbial interactions in marine environments, and exploring the therapeutic potential of natural compounds for neurological disorders and infectious diseases.

Paul W Burridgeمشاهده پروفایل

دانشیار

• Pharmacogenomics
• Cardio-Oncology
• Induced Pluripotent Stem Cell Modeling
• +۵ مورد دیگر

Paul W Burridge, PhD is an Associate Professor in the Department of Pharmacology at Northwestern University's Feinberg School of Medicine and a founding faculty member of the Center for Pharmacogenomics. His laboratory specializes in human induced pluripotent stem cell (hiPSC) modeling for pharmacogenomics and cardio-oncology research. Dr. Burridge's research focuses on understanding how genomic variation influences drug efficacy and toxicity, particularly in cancer therapy-induced cardiovascular complications. His lab pioneered several key methodologies including the first directed cardiac differentiation protocol, non-integrating blood-to-iPSC reprogramming, and chemically defined differentiation protocols. Current projects span cardio-oncology, arrhythmia mechanisms, regenerative medicine, hiPSC models of breast cancer, and cultivated meat applications. Analysis of his 15 most recent publications reveals a strong emphasis on pharmacogenomics of anthracycline cardiotoxicity, with significant focus on genomic risk prediction in childhood cancer survivors, molecular mechanisms of cardiotoxicity, and development of cardioprotective strategies. His work increasingly integrates large-scale genomic analysis with hiPSC modeling to establish causal relationships between genetic variants and clinical outcomes. Fellow of American Heart Association (2016) Recipient of NCI R01 grant for Nilotinib Induced Artery Disease research NIH NHLBI Pathway to Independence Award recipient Editorial Board Member, Journal of Molecular and Cellular Cardiology (2020-present) Associate Editor, JACC CardioOncology (2018-present) Dr. Burridge advises multiple postdoctoral fellows including Ning Ge (cardiac arrhythmia modeling), Praeploy Pongpamorn (chemically defined differentiation), Nnamdi Uche (population-specific doxorubicin susceptibility), and George Gibbons. His lab has secured substantial grant funding for projects including large-scale hiPSC production, cardiotoxicity screening platforms, and novel drug discovery initiatives. The Burridge lab maintains extensive resources including high-throughput screening systems, CRISPR editing platforms, and bioreactor-based differentiation systems, all developed with a focus on eliminating animal-derived products from research.

Andrew Kingمشاهده پروفایل

استادیار

• Medical Toxicology
• Emergency Medicine
• Poison Control
• +۵ مورد دیگر

Andrew King is an Assistant Professor at Wayne State University School of Medicine and serves as Medical Toxicology Fellowship Director at Children’s Hospital of Michigan. He holds concurrent appointments as Medical Director of the Michigan Poison & Drug Information Center and Attending Physician at Sinai Grace Hospital, Detroit Receiving Hospital, and Children’s Hospital of Michigan. His clinical practice spans emergency medicine and toxicology. Education: M.D. from Washington University in St. Louis (2004-2008) B.A. from Northwestern University (2000-2004) Emergency Medicine Residency (Chief Resident) at University of Pittsburgh (2008-2011) Medical Toxicology Fellowship at University of Pittsburgh (2011-2013) Research Focus: Dr. King specializes in clinical toxicology with emphasis on poison control, envenomations, organophosphate poisoning, and cardiotoxicology. His work integrates emergency medicine protocols with toxicological interventions for substance overdoses, metabolic toxicities, and environmental exposures. Publication Trends: His 15 most recent articles (2012-2016) predominantly address toxicology case management, including innovative treatments for envenomations, antidotal therapies for poisonings, and diagnostic challenges in drug overdoses. Recurring themes include organophosphate/carbamate toxicity, sympathomimetic syndromes, and metal/chemical exposures. Awards & Honors: Distinguished Teacher of the Year (Sinai Grace/DRH Residency Programs, 2015) MTF Medical Toxicology Practice Award (2013) Resident Clinician of the Year (Pittsburgh, 2011) Alpha Omega Alpha Honor Society (2008) Professional Leadership: As Fellowship Director, he oversees toxicology training programs and advises medical fellows. He chairs committees for the American College of Medical Toxicologists (ACMT) and reviews manuscripts for multiple peer-reviewed journals including Journal of Medical Toxicology . Laboratories & Teams: Directs clinical operations at Michigan Poison & Drug Information Center, coordinating toxicology consultations and research collaborations across Detroit Medical Center hospitals.

• Non-small cell lung cancer
• Multimodality therapy for locally advanced lung cancer
• Treatment options for high-risk patients with early stage lung cancer
• +۴ مورد دیگر

Jessica Donington is a Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago. She is a prominent figure in thoracic oncology with leadership roles including surgical chair for the thoracic malignancy group of NRG Oncology Group, council member for the Western Thoracic Surgical Association, and immediate past-president of both the New York Society for Thoracic Surgery and Women in Thoracic Surgery. Dr. Donington earned her BS in Biology from the University of Michigan (1987), MD from Rush University (1992), completed General Surgery training at Georgetown University (1999), Cardiothoracic Surgery at Mayo Clinic (2002), and a Surgical Oncology fellowship at NIH/NCI (1996). She also holds an MS in Clinical Research from NYU (2010). Her research focuses on non-small cell lung cancer with particular expertise in multimodality therapy for locally advanced disease, treatment options for high-risk patients with early stage lung cancer, and lung cancer in women. Her work bridges clinical practice with research innovation , addressing critical gaps in thoracic oncology care. She has been instrumental in developing clinical guidelines and advancing surgical approaches for lung cancer management. Analysis of her recent publications (2024-2025) reveals three major research trajectories: 1) Development of clinical practice guidelines for lung cancer management across multiple professional societies; 2) Investigation of healthcare disparities and equity in surgical care; and 3) Advancement of diagnostic and treatment approaches for complex thoracic malignancies. Her work consistently emphasizes evidence-based practice and patient-centered care. Dr. Donington has been actively involved in mentoring and advancing women in thoracic surgery, serving as past president of Women in Thoracic Surgery. Her leadership extends to numerous national committees focused on improving thoracic surgical care, cancer treatment protocols, and professional standards in academic medicine. She maintains an active research laboratory and clinical program focused on improving outcomes for lung cancer patients, with particular attention to high-risk populations and innovative treatment approaches. Her work integrates surgical expertise with multidisciplinary cancer care to optimize patient outcomes.